Candel Therapeutics (CADL) Cash from Investing Activities (2020 - 2025)
Candel Therapeutics recorded quarterly Cash from Investing Activities of -$409000.0 in Q4 2025, down 249.57% quarter-over-quarter from -$117000.0 in Q3 2025, and down 13533.33% year-over-year from N/an in Q4 2024.
Candel Therapeutics' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at -$409000.0 for Q4 2025.
- In Q4 2025, Cash from Investing Activities fell 13533.33% year-over-year to -$409000.0; the TTM figure through Dec 2025 stood at -$560000.0 (down 3400.0% YoY), while the FY2025 annual figure was -$560000.0, down 3400.0% from the prior year.
- Cash from Investing Activities came in at -$409000.0 for Q4 2025 at Candel Therapeutics, down from -$117000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $19000.0 in Q1 2023 to a low of -$710000.0 in Q2 2021.
- A 5-year average of -$209894.7 and a median of -$169000.0 in 2023 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities surged 111.11% in 2023 and sank 13533.33% in 2025, its largest moves.
- Candel Therapeutics' Cash from Investing Activities stood at -$504000.0 in 2021, then jumped by 45.24% to -$276000.0 in 2022, then surged by 90.22% to -$27000.0 in 2023, then surged by 88.89% to -$3000.0 in 2024, then tumbled by 13533.33% to -$409000.0 in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$409000.0, -$117000.0, and -$31000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -428.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Candel Therapeutics | 449.62 Mn | 449.62 Mn | - | -409,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -409,000.00 |
| Dec 31, 2025 | -409,000.00 |
| Sep 30, 2025 | -117,000.00 |
| Sep 30, 2025 | -117,000.00 |
| Jun 30, 2025 | -31,000.00 |
| Jun 30, 2025 | -31,000.00 |
| Mar 31, 2025 | -3,000.00 |
| Mar 31, 2025 | -3,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Jun 30, 2024 | -6,000.00 |
| Jun 30, 2024 | -6,000.00 |
| Mar 31, 2024 | -7,000.00 |
| Mar 31, 2024 | -7,000.00 |
| Dec 31, 2023 | -27,000.00 |
| Dec 31, 2023 | -27,000.00 |
| Sep 30, 2023 | -103,000.00 |
| Sep 30, 2023 | -103,000.00 |
| Jun 30, 2023 | -169,000.00 |
| Jun 30, 2023 | -169,000.00 |
| Mar 31, 2023 | 19,000.00 |
| Mar 31, 2023 | 19,000.00 |
| Dec 31, 2022 | -276,000.00 |
| Dec 31, 2022 | -276,000.00 |
| Sep 30, 2022 | -215,000.00 |
| Sep 30, 2022 | -215,000.00 |
| Jun 30, 2022 | -635,000.00 |
| Jun 30, 2022 | -635,000.00 |
| Mar 31, 2022 | -171,000.00 |
| Mar 31, 2022 | -171,000.00 |
| Dec 31, 2021 | -504,000.00 |
| Dec 31, 2021 | -504,000.00 |
| Sep 30, 2021 | -392,000.00 |
| Sep 30, 2021 | -392,000.00 |
| Jun 30, 2021 | -710,000.00 |
| Jun 30, 2021 | -710,000.00 |
| Mar 31, 2021 | -229,000.00 |
| Mar 31, 2021 | -229,000.00 |
| Dec 31, 2020 | 20.18 Mn |
| Dec 31, 2020 | 20.18 Mn |
| Sep 30, 2020 | -732,000.00 |
| Sep 30, 2020 | -732,000.00 |